Personalized therapy of chronic hepatitis c and b dually infected patients with pegylated interferon plus ribavirin a randomized study

Medicine (United States)

Volumn 94, Issue 42, 2015, Pages e1837-

  Yeh, Ming Lun ^a   Hsieh, Ming Yen ^a   Huang, Ching I ^a   Huang, Chung Feng ^a   Hsieh, Meng Hsuan ^a   Liang, Po Cheng ^b   Lin, Yi Hung ^b   Hou, Nai Jen ^c   Lin, Zu Yau ^d   Chen, Shinn Cherng ^d   Huang, Jee Fu ^a   Dai, Chia Yen ^e   Chuang, Wan Long ^f   Yu, Ming Lung ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^e Institute of Biomedical Science   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; GLUCOSE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS E ANTIGEN; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS ANTIBODY; VIRUS DNA; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

ACUTE HEPATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILL; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HAIR LOSS; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INJECTION SITE REACTION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIXED INFECTION; MYALGIA; NAUSEA; OPEN STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; COMPLICATION; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; MIDDLE AGED;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PRECISION MEDICINE; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84947967625     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001837     Document Type: Article

References (40)

1. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024-1029.
2. Chuang WL, Chang WY, Lu SN, et al. The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study. Cancer. 1992;69:2052-2054.
3. Yang JF, Lin CI, Huang JF, et al. Viral hepatitis infections in southern Taiwan: A multicenter community-based study. Kaohsiung J Med Sci. 2010;26:461-469.
4. Liaw YF. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology. 1995;22:1101-1108.
5. Dai CY, Yu ML, Chuang WL, et al. Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2001;16:636-640.
6. Wong GL, Chan HL, Tse YK, et al. On-Treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014;59:986-995.
7. Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol. 2011;55:554-563.
8. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496.e3-504.e3.
9. Yeh ML, Hung CH, Huang JF, et al. Long-Term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One. 2011;6:e20752.
10. Yu ML, Lee CM, Chen CL, et al. Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up. Hepatology. 2013;57:2135-2142.
11. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology. 2008;47:1884-1893.
12. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-Alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial. Clin Infect Dis. 2008;47:1260-1269.
13. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97-103.
14. Di Martino V, Richou C, Cervoni JP, et al. Response-guided peginterferon plus ribavirin treatment duration in chronic hepatitis C: meta-Analyses of randomized, controlled trials and implications for the future. Hepatology. 2011;54:789-800.
15. Dalgard O, Bjoro K, Hellum KB, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study. Hepatology. 2004;40:1260-1265.
16. von Wagner M, Huber M, Berg T, et al. Peginterferon-Alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology. 2005;129:522-527.
17. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005;352:2609-2617.
18. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007;56:553-559.
19. Okamoto H, Tokita H, Sakamoto M, et al. Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol. 1993;74:2385-2390.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965.
21. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
22. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-Alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
23. Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naive patients with chronic hepatitis C genotype 1 infection. J Hepatol. 2006;44: 275-282.
24. Zeuzem S, Pawlotsky JM, Lukasiewicz E, et al. International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005;43:250-257.
25. Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24-vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: A pilot study in Taiwan. Liver Int. 2006;26:73-81.
26. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24:336-345.
27. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6:409-435.
28. Chuang WL, Dai CY, Chang WY, et al. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-Alpha plus ribavirin combination therapy. Antivir Ther. 2005;10:125-133.
29. Kim YJ, Lee JW, Kim YS, et al. Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean J Hepatol. 2011;17:199-205.
30. Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-Alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008;49:688-694.
31. Dai CY, Huang JF, Hsieh MY, et al. Insulin resistance predicts response to peginterferon-Alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712-718.
32. Fried MW, Hadziyannis SJ, Shiffman ML, et al. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55:69-75.
33. Yu ML, Lee CM, Chuang WL, et al. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis. 2010;202:86-92.
34. Huang CF, Yang JF, Dai CY, et al. Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. J Infect Dis. 2010;201:751-759.
35. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392-420.
36. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-Acting antivirals. Hepatology. 2013;58:428-438.
37. Sarkar S, Lim JK. Advances in interferon-free hepatitis C therapy: 2014 and beyond. Hepatology. 2014;59:1641-1644.
38. Yu ML, Chuang WL. New treatments for HCV: perspective from Asia. Clin Liver Dis. 2015;5:17-21.
39. Pearlman BL, Ehleben C. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. Hepatology. 2014;59:71-77.
40. Bichoupan K, Martel-Laferriere V, Sachs D, et al. Costs of telaprevir-based triple therapy for hepatitis C: $189, 000 per sustained virological response. Hepatology. 2014;60:1187-1195.